Cognitive and behavioural assessment of parkinsonian

syndromes at onset: a longitudinal study by Sambati, Luisa
    
Alma Mater Studiorum ? Università di Bologna 
 
DOTTORATO DI RICERCA IN 
  
Scienze Mediche Specialistiche 
Ciclo XXVII 
 
Settore Concorsuale di afferenza: 06/D6 
Settore Scientifico disciplinare: MED/26 
 
TITOLO  
Cognitive and behavioural assessment of parkinsonian 
syndromes at onset: a longitudinal study 
 
 
 
Presentata da: Luisa Sambati 
 
Coordinatore Dottorato     Relatore 
Egregio Prof. Roberto Di Bartolomeo  Egregio Prof. Pietro Cortelli 
 
 
 
 
 
Esame finale anno 2015 
 
 
IND E X O F C O N T E N TS 
 
1. Introduction  
 
SE C T I O N I : Cognitive assessment of parkinsonian syndromes at onset 
 
2. Patients and Method 
2.1 Inclusion criteria 
2.2 Exclusion criteria 
2.3 Diagnostic procedures 
2.4 Cognitive and behavioural assessment 
2.5 Definition of cognitive impairment 
2.5.1 Inclusion criteria for PD-Mild Cognitive Impairment  
2.5.2 Exclusion criteria for PD-MCI 
2.6 Statistical analysis  
 
3. Results 
3.1 Description of the sample 
3.2 Longitudinal evaluation of cognitive characteristics of patients with a parkinsonian syndrome 
at onset ? brief neuropsychological evaluation 
 
3.3 Longitudinal evaluation of cognitive characteristics of patients with a parkinsonian syndrome 
at onset ? comprehensive neuropsychological evaluation  
Discussion  
3.4 Description of the cognitive characteristics of each syndrome                                              
Discussion  
 
3.5 Cognitive and behavioural assessment of patients with Parkinson disease at onset 
Discussion  
 
 
SE C T I O N I I : Relationship between cognitive and behavioral characteristics with 
demographic and motor features of patients with parkinsonian syndrome at onset 
1.1. Introduction  
3.6 Results 
Discussion 
 
 
 
SE C T I O N I I I : Relationship between cognitive and behavioral characteristics of the 
parkinsonian syndrome with sleep and autonomic features  
1.2 Introduction  
2.7 Method  
3.7 Result 
Discussion 
 
 
 
SE C T I O N I V : Relationship between cognitive and behavioral characteristics of the 
parkinsonian syndrome with depression  
1.3 Introduction  
3.8 Results  
Discussion  
 
 
 
4. Conclusion  
5. Appendix  
5.1 Tables  
5.2. F igures 
 
6. References 
!"
"
Cognitive and behavioural assessment of parkinsonian syndromes at onset: a longitudinal 
study.  
!
1. Introduction  
Parkinsonism, characterized by tremor, rigidity, bradykinesia and postural instability, is a cardinal 
feature of a wide group of neurodegenerative disorders and a common finding in neurological 
outpatient clinics. The incidence ranges from an estimated 0.5/1000 person-years for patients aged 
between 55 and 65 years to 10.6/1000 person-year for those aged above 85 years [1]. Early in the 
course of the disease, establishing a correct diagnosis can be challenging due to overlap in the 
clinical presentation between the various forms of parkinsonism (Table 1). However, being able to 
????????????????????????????????????????????????????????nsonian syndrome (PS) is highly relevant. 
???? ????????????????????????????????????????????????????????????????????????????????? 
neurodegenerative syndrome clinically characterized by resting tremor, rigidity, bradykinesia, 
asymmetric onset and sustained response to levodopa or dopamine agonist [2]. The prevalence 
rates of PD ranged from 108 to 257 per 100,000 persons, and the annual incidence rates ranged 
from 11 to 19 per 100,000 persons [3]. 
The differential diagnosis with PD is broad and includes, among others, multiple system atrophy 
(MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), dementia with 
Lewy bodies (DLB) and secondary causes of parkinsonism (Table 2) [4]. 
Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder characterized clinically by 
various combinations of autonomic, cerebellar, parkinsonian, and pyramidal features [5]. The 
prevalence rate is below 5 and the incidence rate is below 1 in 100,000 [6]. 
Lewy body dementia (DLB) is the second most common cause of neurodegenerative dementia after 
Alzheimer Disease (AD), with a prevalence of 19%. It is clinically diagnosed by a progressive 
cognitive decline sufficient to interfere with normal social or occupational function, fluctuating 
cognition with pronounced variations in attention and alertness, recurrent visual hallucinations and 
spontaneous motor features of parkinsonism [7]. 
?????????????????????????????????????????????????????????????????????????????????????????? 
diagnosis of PDD designates dementia that develops within the context of established PD, whereas 
a diagnosis of DLB is appropriate when the diagnosis of dementia precedes or coincides within 1 
year of the development of motor symptoms [8]. 
Progressive supranuclear palsy (PSP) is characterized by either vertical supranuclear palsy or both 
slowing of vertical saccades and prominent postural instability with falls in the first year of disease 
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onset [9]. Its incidence increases with age, from 1.7 cases per 100,000 per year at 50?59 years to 
14.7 per 100,000 per year at 80?99 years [6]. 
Corticobasal degeneration (CBD), a distinctive pathological condition, is clinically characterized by 
a slow onset and progressive asymmetric cortical and extrapyramidal dysfunction described as 
akinetic rigid syndrome, levodopa-resistant, associated with prominent apraxia, cortical sensory 
loss, focal reflex myoclonus, dystonia, alien limb phenomenon without an early dementia [10]. 
CBD may have several different clinical presentations aside from the Corticobasal syndrome, 
including frontotemporal dementia, primary progressive aphasia, progressive speech and oral 
apraxia, and dementia with behavioral changes, apraxia, and parkinsonism. The relative frequencies 
of these manifestations is unknown [11]. 
Despite advances in our understanding of degenerative parkinsonian disorders, currently there are 
no reliable biomarkers to separate them, and a definitive diagnosis can only be made on 
neuropathological examination [12].  
Efforts to study large de-novo cohorts with longitudinal follow-up are ongoing worldwide [13-18]  
in order to obtain in vivo results of establishing a correct diagnosis early in the course of the 
disease. 
Distinguishing these disorders clinically, particularly in the early stages, poses immense challenges, 
even to movement disorder specialists [12, 19-20]. The diagnostic accuracy of the initial diagnosis 
varies greatly in PD, with accuracies of 76 % in the hands of a general neurologist to up to 90 % by 
movement disorder specialists [21, 22]. Furthermore, a recent study reported that the accuracy for a 
clinical diagnosis of PD is 26% in untreated or not clearly responsive subjects, 53% accuracy in 
early PD responsive to medication, and 85% diagnostic accuracy of longer duration, medication-
responsive PD [23]. 
The diagnostic accuracy is lower for patients with a form of AP, e.g., 41?88 % in PSP; [24] and 50?
66 % in MSA [5]. 
Cognitive impairment is one of the non motor features widely descripted in parkinsonian syndrome, 
it has been related to the motor characteristics of the parkinsonian syndrome, associated with 
neuropsychiatric dysfunction and the characteristic sleep and autonomic features [36-37].  
It has been shown to be highly prevalent at all disease stages and to contribute significantly to 
disability [11].  
Several studies aimed to characterize the cognitive profiles of each parkinsonian disorders [36], 
others [reviewed in 12] aimed to define the contribution of cognitive testing to differentiate 
parkinsonian disorders at onset, reporting conflicting results. This conflicting results could be 
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related both to study design and to the overlap and to the heterogeneity of the clinical picture of 
parkinsonian disorders [12].  
 
Aim of this study is:  
1) to evaluate longitudinally the cognitive and behavioral characteristics of patients with a 
parkinsonian syndrome at onset;  
2)  to describe the cognitive and behavioral characteristics of each parkinsonian syndrome; 
3) to define in PD patients at onset  the presence of  MCI or Parkinson disease dementia;  
4)  to correlate the cognitive and behavioral characteristics with the features of the parkinsonian 
syndrome and with the associated sleep and autonomic features. 
 
2. Patients and Method 
2.1   Inclusion criteria 
We consecutively recruited patients, aged between 18 and 90 years, evaluated at the Movement 
Disorders Centre of our Department for a neurodegenerative disease starting with parkinsonian 
features (tremor, bradykinesia, rigidity, postural instability) and disease duration up to 3 years. 
2.2   Exclusion criteria 
Patients affected by secondary causes of parkinsonism (Table 2)  were excluded.  
2.3  Diagnostic procedures 
Each patient performed the follow evaluations:  
 - clinical history, 
-  neurological examination (including assessment of motor impairment by means of UPDRS 
part III [24]), 
-  neuroimaging studies (brain MRI and DAT Scan), 
-  quantification of motor response to standard oral levodopa test (based on simultaneous serial 
measurements of plasma levodopa concentrations, finger-tapping motor effects, and 
dyskinesia ratings), levodopa equivalent dose (LED) was calculated for each patients [25], 
-  evaluation of autonomic control of the cardiovascular system through cardiovascular reflex tests  
?????????????????????? manoeuvre, Handgrip test, Deep breathing test) [26] and evaluation of 
autonomic dysfunction through the questionnaire SCOPA-AUT: Scales for Outcomes in 
Parkinson's Disease ? Autonomic [27,28],  
-  assessment of sleep disturbance by means of a whole night video-polysomnographic 
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(VPSG) study and through questionnaires ???????????????????????????????????????? [29];  RBD: 
REM sleep behaviour disorder questionnaire [30], BQS: Bologna questionnaire on sleepiness-
related symptoms [31], ESS: Epworth sleepiness scale [32], RLS: Restless Legs Syndrome criteria 
and rating scale [33], PDQ-39: 39-item Parkinson's disease questionnaire [34], 
-  cognitive and behavioural assessment (see below). 
Neuroimaging studies were performed at baseline.  
The other procedures were performed at baseline (T0) and after 16 months (T1).  
Diagnosis was carried out at T1 according with international diagnostic criteria for the diagnosis of 
PD [2], MSA [5], DLB [7], PSP [9] and CBD [10]. 
Patients not fulfilling international diagnostic criteria were diagnosed as parkinsonian syndrome not 
otherwise specified (PS).  
All clinical data useful for diagnosis of PD, MSA, PSP, LBD, CBD were tabulated with full 
details in a database developed ad hoc for this study. 
 
2.4   Cognitive and behavioural assessment 
We built up a neuropsychological assessment in order to recognize the initial cognitive and 
behavioral features of the different parkinsonian syndrome according to the Movement Disorder 
Society Task Force criteria and revision of literature [12-35]. 
Neuropsychological evaluation is described in Table 3.  
All test results were corrected for age, sex and education according to Italian standardizations 
(Table 3). 
 
2.5    Definition of cognitive impairment 
Definition of cognitive deficit: one or more test impaired according to cut-off score corrected for 
age, sex and education according to Italian standardization. 
If at least one test was impaired according to cut-off score of corrected score according to Italian 
standardization the patient had cognitive impairment.  
Impairment in cognitive domain was defined if at least one test was impaired in that domain (for the 
relation cognitive test to cognitive domain, see Table 3).  
Progression of cognitive impairment was defined if one more test was impaired at T1. 
Improvement of cognitive impairment was defined if one test less was impaired at T1. 
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2.5.1 Inclusion criteria for PD-Mild Cognitive Impairment  
A further analysis was conducted in patient with PD. Patients with a d????????????????????????
disease [20] and gradual decline in cognitive ability reported by either the patient or informant, or 
observed by the clinician; cognitive deficits on either formal neuropsychological testing or a scale 
of global cognitive abilities according to Specific guidelines for PD-MCI level II categories (Table 
11) [38];  cognitive deficits are not sufficient to interfere significantly with functional 
independence, although subtle difficulties on complex functional tasks may be present. 
2.5.2 Exclusion criteria for PD-MCI 
Diagnosis of PD dementia based on MDS Task Force proposed criteria [18], other primary 
explanations for cognitive impairment (e.g., delirium, stroke, major depression, metabolic 
abnormalities, adverse effects of medication, or head trauma), other PD-associated comorbid 
conditions (e.g., motor impairment or severe anxiety, depression, excessive daytime sleepiness, or 
psychosis) that, in the opinion of the clinician, significantly influence cognitive testing. 
 
2.6   Statistical analysis  
Descriptive analysis of demographic and neuropsychological data has been reported.  
 
3. Results 
 
3.1     Description of the sample 
 
We recruited 91 patients. 
6 patients dropped-out after the baseline evaluation (Table 4. Demographic data of dropped-out 
patients). 
55 of 91 patients completed the second evaluation (T1).  
According to international diagnostic criteria 39 patients were diagnosed as PD, 2 as CBS, 1 as 
MSA, 2 as PSP, 11 as PS not otherwise specified. 
55/55 patients performed the brief  neuropsychological evaluation both at T0 and T1. 
20/55 (14 PD, 5 PS, 1 CBS) patients performed the comprehensive neuropsychological evaluation 
both at T0 and at T1. 
Demographic and clinical data are shown as mean and standard deviation in Table 5.  
The means and standard deviations results of the cognitive battery administered to patients 
are presented in Table 6 and 7. 
At T0, 29 (23 PD and 6 PS)  patients did not present cognitive impairment.  
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13 (7 PD, 4 PS, 1 CBS, 1 MSA) patients were impaired in one domain: 
? 12 (6 PD, 4 PS, 1 CBS, 1 MSA) in attention or executive function; 
? 1 PD in fluency.  
In one case (MSA) the impairment in one cognitive domain was related to an impairment in 3 test 
(assessing the same cognitive domain), in the other cases only one test per domain was impaired.  
6 PD patient were impaired in two domains: 
? 2 were impaired in executive function and verbal memory; 
? 1  in executive function and attention; 
? 2 in attention and fluency;  
? 1 in verbal memory and fluency;  
In two cases (PD) the impairment in one cognitive domain was related to an impairment in 2 test 
(assessing the same cognitive domain), in the other cases only one test per domain was impaired.  
4 patients were impaired in three cognitive domains: 
? 2 (1 PSP, 1 PD) attention and executive function and fluency; 
? 1 PD was impaired in attention and fluency and verbal memory; 
? 1 CBS was impaired in attention and fluency and praxis. 
In two cases (PD, PSP) the impairment in one cognitive domain was related to an impairment in 2 
test (assessing the same cognitive domain), in the other cases only one test per domain was 
impaired.  
2  patients (1 PD, 1 PS)  were impaired in four cognitive domains: 
? 1 PD was impaired in attention and executive function and verbal memory and fluency;   
? 1 PS  was impaired in attention and executive function and verbal memory and visuospatial 
function. 
In both cases two test were impaired at least for one of the impaired domains.  
One patient (PSP) showed a global cognitive impairment. 
 
3.2  Longitudinal evaluation of cognitive characteristics of patients with a parkinsonian 
syndrome at onset ? brief neuropsychological evaluation 
22/55 patients (17 PD and 5 PS) did not present cognitive impairment both at T0 and at T1.  
18/55 patients presented a progression of cognitive impairment (at least one more cognitive domain 
impaired at T1): 
- 6/18 (5 PD and 1 PS) patients were not impaired a T0 and presented a progression of cognitive 
impairment at T1: 
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? 5 PD patients presented an impairment in attention or executive function; 
? the PS patient presented an impairment in verbal memory.  
- 12/18 patients (6 PD , 2 PSP, 1 CBS, 3 PS) presented a progression of cognitive impairment: 
? 2 PS were impaired in attention and executive function; 
? 1 PD was impaired in attention and executive function and praxis;  
? 2  PD were impaired in attention and executive function and verbal memory;  
? 1 PSP was impaired in attention and executive function and verbal memory and fluency; 
? 1 PD and 1 CBS in attention and executive function and praxis  and fluency; 
? 4/18 (2 PD, 1 PSP, 1 PS) patients presented a progressive global cognitive impairment. 
Figure 1 shows the progression of cognitive impairment from T0 to T1.  
8/55 (6 PD and 2 PS) patients presented an improvement of cognitive deficits at T1. 
7/55 patients (5 PD, 1 MSA, 1 CBS) remained stable at T1. 
Figure 2,3 and Table 8 show the percentage of patients failing each neuropsychological test in 
progressive and not progressive patients.    
26 out of 55 patients (47%) failed at least one test in the neuropsychological test at T0. 
Most of the patients failed to perform correctly STROOP and SVAT, WF and BARR in both groups 
of patients. The frequency of impairment was less than 15% on the remaining test. 
In the comprehensive battery,  some test (RFC, BS, CS, TMT, MP, Token) were performed 
correctly in the whole group/by all the patients. (Table 8 and 9. Impaired test and domain).  
The domains failed by most of the patients were attention (n =45 ), executive function (n =36), 
verbal memory (n =21) and fluency (n=21) equally affected; almost equally affected (praxis, 
visuospatial memory and cortical sensibilities).  Comprehension was spared.  
Considering the 18 patients with a progression of cognitive impairment only 5 of them at T0 and 7 
of them at T1 presented a deficit in test or battery evaluating global cognitive impairment: 
At T0  
? 2 PS-PSP; 
? 3 PD (patient 28: FR BBDM, attention and executive function and verbal memory; patient 
22:  FR BBDM, progressive global cognitive impairment, patient 10: MMSE, progressive 
global cognitive impairment). 
At T1 
? 2 PS-PSP; 
? 1 CBS; 
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? 3 PD (patient 59: FR BBDM, attention and executive function and verbal memory; patient 
25: FR BBDM, attention and executive function and praxis and fluency; patient 10: MMSE 
progressive global cognitive impairment); 
? 1 PS  (patient 51presented a significant progression LTVM, SVAT, WF, BARR, STROOP). 
The other PD progressive patient (patient 5, impaired in attention and executive function and 
praxis) did not present impairment in FR BBDM and MMSE. 
 
3.3    Longitudinal evaluation of cognitive characteristics of patients with a parkinsonian 
syndrome at onset ? comprehensive neuropsychological evaluation  
20 (14 PD, 5 PS, 1 CBS) patients performed the comprehensive evaluation. 
Of these patients:   
? 1 PD did not present cognitive impairment both at T0 and T1; 
? 2 (1 PD, 1 PS)  patients presented an improvement of cognitive impairment ; 
? 10 (7 PD, 1 CBS, 2 PS) patients presented a stability of cognitive impairment; 
7/20 (5 PD, 2 PS ) patients presented a progression of cognitive impairment (at least one more 
domain impaired): 
-  4/ 7 patients (3 PD and 1 PS) were not impaired at T0 and presented a progression of cognitive 
impairment at T1. These  patients presented an impairment in attention or executive function. 
- 3/7 (2 PD, 1 PS) presented a progression of cognitive impairment: 
? 1 PS was impaired both in attention and executive function;  
? 1 PD was impaired in attention and executive function  and verbal memory; 
? 1 PD was impaired in executive function  and verbal memory and visuospatial function.  
 
Discussion  
Patients with parkinsonian syndrome and progressive cognitive impairment showed mainly an  
impairment in attention and executive function, both at onset and during the progression of the 
disease.  
Comparing the neuropsychological evaluation performed at T0 with the longitudinal evaluation at 
16 months, we observed that 29% of patients presented a progression of cognitive impairment,  
15% showed an improvement in cognitive evaluation, 13% of patients were stable and  41% of 
patients did not show impairment both at T0 and T1. 
According to these findings, the evaluation of cognitive function at onset in patients with 
parkinsonian syndromes is mandatory to document early cognitive decline and its frequency, to 
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identify motor and non motor correlates of impaired baseline cognition and to understand 
phenotypic heterogeneity.  Furthermore neuropsychological evaluation at follow-up  is necessary to 
detect longitudinal changes of the cognitive impairment, including the pattern of impairment, its 
eventual progression, especially in patients with a suspicion of dementia or typical syndrome. In 
atypical presentation of parkinsonian syndrome neuropsychological evaluation is even more 
essential for the clinician that should be able to build a clinical profile in conjunction to the other 
features of parkinsonian syndrome [90].  
Furthermore, our study confirm the need of a complete neuropsychological evaluation as test 
assessing global function as MMSE could be not enough sensitive to disclose and to describe 
different pattern of impairment. On the contrary, the detection of normal MMSE could be not 
enough specific, either at follow-up, to exclude cognitive dysfunction. 
Although a detailed neuropsychological evaluation could be important to define the characteristic of 
cognitive impairment, the majority of the test in the comprehensive battery were always normal. 
F???????????????????????????????????? could be overloaded for several reason: some of our patients 
showed just a test impaired despite several test assessing the same cognitive domain, probably 
overestimating the cognitive impairment.  
The aim to identify bedside cognitive tests, analogous to clinical signs, that may assist clinicians in 
differentiating parkinsonian disorders has to be discussed considering that cognitive tests never 
purely assess a single cognitive domain and that, on the contrary, cognitive domains are similarly 
multifaceted, so that they cannot be fully assessed by a single test (Table 3).  Furthermore, it has to 
be taken into account the confounding factors of motor impairment in test assessing cognitive  
function by means of a motor act (for example TMT and BARR).  
It means also that the use of a well structured battery, discussing the utility of test that need motor 
act, is one of the most important issue in recognizing cognitive impairment in parkinsonian 
syndrome.  
!"#
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3.4 Description of the cognitive characteristics of each syndrome (Table 6 and 7) 
At T0, the different disease group were characterized by a different pattern of impairment. 
In particular the MSA patient showed a subtle remittent impairment of attention and executive 
function, reporting impaired performance according to cut-off scores only in subtest exploring 
attentive function (IVM, BARR, STROOP) and on the contrary, results to the other test (STVM 
LTVM IVM SVAT WF) similar to the group of not impaired patients.  
PSP showed a global cognitive impairment, reporting the lowest score in the majority of the 
performances, both in respect to the other subgroups of impaired patients and cut-off scores. PSP 
patients did not achieve scores similar to the group of not impaired patients. 
PD and PS patients presented a heterogeneous pattern of cognitive impairment, reporting 
intermediate scores of cognitive performance in respect to the other groups of patients, and in both 
subgroups of patients no similar progression of cognitive impairment was been observed . 
In both subgroups of patients attention and executive function were the domains failed by most of 
the patients. In respect to cut-off scores, PD were never impaired while PS were impaired in test 
assessing attentive function (BARR and STROOP). 
We observed two DCB patients. Both patients were impaired in executive function and praxis, 1 of 
the two patients within a global cognitive impairment. In respect to the other groups, CBD 
presented lower CD scores, impaired considering cut-off scores. Results to the other test (STVM 
LTVM IVM SVAT WF) were similar to the group of not impaired patients. 
Considering test assessing global cognitive impairment, the analysis revealed that 2/2 (100%) of 
PSP patients were impaired and  1/2 CBD (50%) and 4/ 39 PD (10 % of PD patients).  
The other subgroup of patients did not present a global cognitive impairment. 
 
Discussion 
Previous studies identified numerous cognitive tests able to differentiate parkinsonian disorders 
with statistical significant difference, but without a real clinical significance [36, 38-39]. 
According to our results, the contribution of each neuropsychological test to diagnosis at onset is 
not very useful.  Furthermore, as discussed in the previous section, this evaluation should be made 
at onset and at follow-up. In addition, a standardized well structured battery of widely available, 
cost-effective, and easy-to-administer tests should be used in order to ensure translatability into 
clinical practice.  Although the role of each cognitive testing may be of limited benefit in 
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differential diagnosis, it is still important to document neuropsychological deficits and profile for 
several very practical purposes.  
Our study confirm previous report [36] discussing the characteristic cognitive profiles of each 
parkinsonian disorders. Furthermore our data suggest a common pattern of impairment (deficit in 
BARR T, WF, STROOP T and E; Frontotemporal Dementia like) across the different parkinsonian 
syndrome with an analogous common pattern of normality (sparing of long term memory).  
In this optic, as with other clinical signs, cognitive features reflect the topographic distribution of 
pathology, regardless of the pathology type [39-40]. Thus, cognitive features arguably predict 
clinical syndromes rather than underlying pathologies. However, some clinical syndromes, when 
presenting in their classic form, are reasonably predictive of the underlying type and distribution of 
pathology.  Characteristic cognitive features are therefore good surrogate predictive markers of 
underlying pathologies when applied to classic presentations. Their usefulness reduces as the 
???????????????????????????????????????????????????????? clinical spectrum of a disease. The clinician 
must therefore bear in mind the potential clinical overlap of different pathological entities.  
Furthermore, serial cognitive testing in the clinic may avoid missing the evolution of dementia and 
highlight deficits of such severity ????????????????????????????????????????????????????? clear 
implications for therapeutic and other management decisions.  
 
3.5 Cognitive and behavioural assessment of patients with Parkinson disease at onset 
We recruited 39 PD patients.  
Demographic and clinical data on all included patients are shown in Table 5.  
The means and standard deviations for results of the cognitive battery administered to patients 
are presented in Table . 
At T0 22/39 PD patients did not present cognitive impairment. 
At T1 27/39  patients did not present cognitive impairment. 
6 PD- MCI  were diagnosed at T0. 
Of these patients 4 were multiple amnestic , 1 multiple non amnestic, 1 single amnestic. 
At T1, 7 patients were diagnosed as PD-MCI. 
Of these 7 patients 3 were diagnosed as PD-MCI at T0. 
1/ 4 PD-MCI multiple amnestic patients evolved in single amnestic patients,  
2/4 (patients 10 and 22) remained multiple amnestic,  
The remaining 4 patients did not present cognitive impairment at T0. 
All these patients presented a non amnestic impairment (3 multiple, 1 single). 
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The other 3 patients (multiple amnestic, multiple non amnestic, single amnestic)  impaired at T0 did  
not present cognitive impairment at T1. 
 
The other 11 patient at T0 and 5 patients at T1 presented different degree of cognitive impairment 
not  accomplishing the diagnosis of PD-MCI.  
 
Discussion  
 
Cognitive impairment and dementia are common in ?????????????????????????????????????-term 
cumulative prevalence of 80% for PD dementia (PDD) [41]. According to a recent study,  Mild 
Cognitive Impairment,  appears to be common even in newly diagnosed, drug-naive PD patients 
[42].  Previous studies evaluated the presence of cognitive impairment at PD onset and at follow-up 
[43-45] but no study assessed the diagnosis of PD-MCI during the follow-up. 
This study investigated the presence of MCI in a sample of 39 de novo PD patients.  
The prevalence of PD-MCI at T0 and at T1 was respectively 15% and 17%, similar to the 14.8% 
reported by Poletti  and colleagues. Previous studies reported an higher prevalence of MCI in PD 
patients ranging between 18 and 36%. Conversely, the evaluation of the stability of the diagnosis of 
MCI at follow-up in the sample of  newly diagnosed drug-naive PD patients was 5%.  
According to our knowledge this is the first study evaluating the stability of the diagnosis of MCI at 
follow-up.  
Previous studies reported older age and the higher severity of bradykinesia as clinical features 
associated with PD-MCI. These findings cannot be clearly discussed in relation to our results due to 
the small number of patients diagnosed as PD-MCI. 
The evaluation of MCI in PD patients should be taken into account as a possible predictor of 
disease severity, has a major impact on ??????????independence, patients and caregivers quality of 
life.  
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Relationship between cognitive and behavioral characteristics with demographic and motor 
features of patients with parkinsonian syndrome at onset 
 
1.1 Introduction  
Cognitive impairment is increasingly recognized in parkinsonian patients and especially in 
Parkinson disease??????????? since the early stages.  
Several studies evaluated the demographic and motor features of parkinsonian patients reporting 
advanced age, lower education,  male sex, severity of motor disease, postural instability, and an 
akinetic-rigid syndrome as the main risk factors for cognitive impairment, expecially in PD patients  
[46-49]. 
Considering PD patients, one longitudinal study observed a 52% prevalence of dementia with over 
4-years follow-up and 60% (95% confidence interval, 54?66%) prevalence of dementia with over 
12-years follow up in 233 patients with PD [46] and an incremented 65% risk of dementia by age 
85 years [46]. Furthermore, some studies demonstrated that cognitive disturbances in  PD patients 
cannot be attributed to drug treatment, but are likely to be directly related to the pathology of the 
disease  [48] .   
 
3. 6 Results 
Progressive cognitively impaired patients showed higher age at onset, UPDRS at T0 and at T1, and 
HY score compared to not impaired patients (Table 5).  
 
Discussion 
Several studies reported an association between higher age at onset and a worst motor phenotype 
(higher UPDRS and HY, bradikinetic-rigid type) and cognitive impairment.  
Our study confirm these data and report an even worser motor phenotype in patients with a 
progression to dementia.  
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Relationship between cognitive and behavioral characteristics of the parkinsonian syndrome 
with sleep and autonomic features  
 
1.2 Introduction  
Primary sleep disorders such as REM sleep behaviour and sleep breathing disorder are common 
non-motor symptoms in parkinsonian patients.  
REM sleep behaviour disorder is a sleep parasomnia characterized by dream-enacting behaviours, 
often violent and injurious, occurring during REM sleep and associated with loss of the 
physiological REM muscle atonia [50]. According to the second edition of the 
ICSD, a clinical diagnosis of RBD can only be made when a patient displays violent, 
potentially violent or sleep-disruptive dream-enactment behaviour along with REM sleep 
without atonia (RWA) as determined by VPSG. This condition may be either idiopathic (iRBD) or 
associated with another neurologic disorder [51]. RBD affects about 33?46% of PD patients [52-
53],75% of DLB patients [54], and almost 100% of MSA patients [55].The onset of RBD can 
precede, by years, the onset of these diseases [57-59]. For this reason several studies have tried to 
disclose signs predictive of the future development of a neurodegenerative disease in patients with 
iRBD by means of clinical, neuropsychological, electrophysiological and neuroradiological 
modalities. Several studies have investigated whether presence of these dysfunction in iRBD 
predicts the subsequent development of a neurodegenerative diseases.  
Cognitive impairment has been widely evaluated in patients with  iRBD patients. In general, 
attention, executive functions, episodic verbal memory (mainly free recall capacities), and non- 
verbal learning are the most affected domains in iRBD [60-65]. Additionally, some studies reported 
in iRBD anomalies in visuospatial/visuoperceptive abilities [60, 64-65], but this remains 
controversial  [62-52]. However, results vary across studies depending on which cognitive domain 
is impaired. Population heterogeneity, small sample size, and the use of different cognitive tasks 
with variable sensitivity to detect deficits and variable specificity to a cognitive domain may explain 
these discrepancies. Infact, the presence of visuospatial (or non-verbal learning) impairment appears 
to be related to the extent of cognitive decline in iRBD patients [58, 65- 66], as reported in RBD-
associated neurodegenerative diseases such as PD or DLB [54,63]. On the other hand, language and 
praxis appear to be well preserved in iRBD, although these functions have received little research 
attention. 
Sleep-disordered breathing is characterized by snoring and sleep apnea of various severity. An 
abnormal breathing event is defined as snoring (clear inspiratory noise over the trachea), apnea 
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(defined as a stop in airflow of at least 10s, complete ?????????????????????????????????????????
(reduction of 50% of the flow, with an oxygen desaturation of >4% and lasting at least 10s; ??????
decrease in airflow >10 s). The snoring and apnea/hypopnea indices, i.e., average number of 
respective events/hour of sleep, serves to quantify sleep-disordered breathing. By convention, a 
???????????????????????????????????????????????????????????????????????????????????????????????
presence of sleep apnea.  The number of apneic events is calculated as the apnea/hypopnea index 
(AHI),i.e., the total amount of apneas and hypopneas per hour of sleep. An AHI lower than five 
identifies a normal subjects, an AHI between 5 and 15 identifies mild OSA, an AHI between 15 and 
30 a moderate OSA and an AHI greater than 30 a severe OSA [50]. 
Several studies suggest that apnea recurrence, sleep fragmentation, day- time sleepiness, and 
nocturnal hypoxemia may induce an impaired cognitive function in OSA patients [67-70] affecting 
vigilance, attention, psychomotor performance, executive function and memory [71-73]. However, 
the presence and the extent of the cognitive changes in OSA subjects is still a matter of debate [74-
75]. Results of studies on cognitive function in OSA are heterogeneous, the controversial results 
may be partially explained by the severity of the disease, a minor cognitive impairment present in 
mild cases [76-78] and a greater deficit particularly in terms of executive function [71,79] in severe 
cases.  
Only one study [80] evaluated  the impact of sleep disorders (through VPSG) on non-motor 
symptoms in patients with Parkinson disease (PD) (through  questionnaire and global scale) and 
concluded that having sleep disorders (particularly RBD and RLS but not OSA) was a predictor of 
overall non-motor symptoms in PD.##
Considering autonomic features, orthostatic hypotension (OH) is the cardinal sign of sympathetic 
neurocirculatory failure. It is defined as a sustained reduction in systolic blood pressure (SBP) of at 
least 20 mmHg or, in diastolic BP (DBP) of at least 10 mmHg, within three minutes of standing up 
or head-up tilt to at least 60° on a tilt table [81].  
OH can be caused by vascular, pharmacological or neurogenic factors (nOH). nOH can be related to 
preganglionic neurodegenerative disease, i.e. multiple system atrophy (MSA), or to 
????????????????????????????????????????????????????????????????????????????????????????????????
(PAF), autoimmune autonomic ganglionopathy (AAG) associated with antiacetylcholine receptor 
antibodies (AchR) or to metabolic disease.  
Considering that several disorders occur with OH, CI or both, regardless of the aetiology, many 
studies have been conducted in order to define the increased coexistence of the two conditions and 
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their causal relationship [37]. Although their identification could be relevant for diagnostic, 
prognostic and therapeutic outcomes, the results of these studies remain controversial [37].  
 
2. 7 Method  
All patients underwent a full night VPSG including EEG (C3-A2, O2-A1, CZ-A1), right and 
left electro-oculogram (EOG), surface EMG of mentalis, bilateral wrist extensor and tibialis 
anterior muscles, EKG, microphone, oro-nasal, thoracic and abdominal respirograms, 
systemic arterial pressure, oxygen saturation and continuous audiovisual acquisition. A sleep 
laboratory technician monitored each recording. Sleep stages and tonic and phasic 
components of REM sleep were scored according to the American Academy of Sleep 
Medicine (AASM) criteria. According to ASSM and the ICSD (ICSD, 2005) 
criteria, we evaluated: 
- arousal events: the number of arousals and the arousal index (AI) (index: number of 
events per hour of sleep); 
- respiratory events: number of obstructive/central/mixed apnoeas/hypopnoeas and 
apnoea/hypopnoea index (AHI) 
- movement events: PLMS, PLMS index, PLMS/arousal index; excessive fragmentary 
myoclonus (EFM), hypnic jerks (HJs) and RBD. 
PLMS and other simple (EFM, HJs) or complex motor events during sleep (RBD) were 
checked against the video recording. The tonic and phasic components of REM sleep were 
scored separately, according to AAMS criteria. Each 30-second epoch was scored as tonic or 
atonic depending on whether tonic chin EMG activity was present for more or less than 50% 
of the epoch. In each patient, phasic EMG activity was evaluated in mini-epochs of 3 seconds 
in all REM sleep periods; a phasic EMG event was defined as any burst of EMG activity 
lasting 0.1-5.0 seconds with an amplitude exceeding at least 4 times the background EMG 
activity. Each VPSG was scored by a neurologist blinded to the clinical diagnosis. 
 
All patients underwent the evaluation of autonomic control of the cardiovascular system through 
cardiovascular reflex tests. Orthostatic hypotension (OH) was defined as a sustained reduction in 
systolic blood pressure (SBP) of at least 20 mmHg or, in diastolic BP (DBP) of at least 10 mmHg, 
within three minutes of head-up tilt to at least 60° on a tilt table during tilt test according to 
international diagnostic criteria [81].   
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3.7  Results 
 
9/55 patients showed RBD. Of these 9 patients, 5 (1 PS, 1 MSA, 3 PD) were not cognitively 
impaired and 4 (1 PD, 3 PS) showed a progression of cognitive impairment.   
5/55 patients were affected from OH. Of these 5 patients, 3 (1 PS, 1 MSA, 1 PD) were not 
cognitively impaired and 2 PS showed a progression of cognitive impairment.   
10 patients were affected from OSA. Of these 10 patients, 5 (3 PS, 2 PD) were not cognitively 
impaired, of these 3 presented an improvement of OSA; and 5 (1 PSP, 1 PS, 3 PD)  showed a 
progression of cognitive impairment, 4 presented an improvement of OSA. 
 
Discussion 
 
Several studies [reviewed in 37] addressed the question of the relationship between cognitive 
impairment and OH in the parkinsonian syndrome reporting no association between the two. 
Similarly our study did not disclose an association between progressive cognitive impairment and 
OH. 
On the contrary, studies addressing the question of  the relationship between cognitive impairment 
and RBD reported a striking specificity of idiopathic RBD in converting to parkinsonism or 
dementia after a range of onset from 14 to 29 years.  No study discussed the relation between RBD  
and cognitive impairment at the onset of parkinsonian syndrome.  In our sample the disease 
duration is 19 months and that our study assess the presence of RBD trough both VPSG and sleep 
questionnaire reporting a prevalence of 16% (9/55 patients), 4 of these patients presented a slightly 
progressive cognitive impairment.  
Similarly OSA was not associated with a diagnosis of cognitive impairment. 
In this study, progression of cognitive impairment is not associated to OH nor RBD or OSA.  
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Relationship between cognitive and behavioral characteristics of the parkinsonian syndrome 
with depression  
 
1.3 Introduction  
Neuropsychiatric symptoms including depression, anxiety, apathy and psychosis [36] are common 
in parkinsonian patients, affecting the majority of patients at some time during the course of 
disease. Among the most common, and most important, neuropsychiatric symptoms are depression, 
anxiety, apathy and psychosis [82].  
?????????????????????????????????????????????????????????? ranging from 17 to 70% [83]. Although 
apathy and depression have been clearly dissociated as independent syndromes in PD [84], 
symptoms of apathy and depression may also overlap [85]. 
Depression is twice as common in patients with PD as in healthy controls,4 affecting 31% of 
patients [85] ; it may predate the onset of motor impairment [86]. 
Similarly, manifested neuropsychiatric symptoms are common in parkinsonian syndromes.  
CBD patients are mostly depressed and the majority of them may manifest apathy, irritability and 
agitation at onset or during the course of the disease.  
In several small studies examining the neuropsychiatric symptoms in PSP, results have 
mirrored those exhibited by apathetic patients with dementias of the frontal lobe [36]. For example, 
negative symptoms (i.e., apathy, aspontaneity, and indifference) can 
dominate the neuropsychiatric profile of these PSP patients, with apathy being the most 
common negative symptom [36] . Depression is another common symptom in PSP, although rates 
vary among studies [87]. 
Patients with CBD showed significantly more depression than both patients with PSP and controls; 
conversely, patients with PSP were more apathetic [87, 88] . 
Less common neuropsychiatric symptoms include anxiety and irritability [87,88] 
According to literature,  MSA patients showed less common neuropsychiatric symptoms if 
compared with the other parkinsonian syndromes [89]. 
 
3.8 Results  
At T0 15 patients (6 PD, 2 PSP, 2 CBS, 1 MSA, 4 PS) were depressed according to BDI. Of these 
patients, 8  (1 juvenile PD, 2 PSP, 3 PS, 1 MSA, 1 CBS, 2 PSP) patients remained depressed  at T1. 
At T0 8 (7 PD, 1PS) patients reported pathological results at STAI-1 and 7 (4 PD, 2 PS, 1 CBS) 
patients at STAI-2.  3 PD patients reported the same pathological results at T1.  
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At T1 10 patients (7 PD, 1 MSA, 2 PS) patients reported pathological results at STAI-1 and 12 (8 
PD, 3 PS, 1 MSA) patients at STAI-2. 
Apathy was diagnosed in 2 patients (1 PS, 1 CBS).  
 
Discussion  
Our results showed that depression was more common in patients with parkinsonian syndrome 
while anxiety was more common in patients with PD.  
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4. Conclusion  
Several characteristics of parkinsonian syndrome have been evaluated in order to find a predictor of 
correct diagnosis early in the course of the disease. According to our finding the different feature of 
parkinsonian syndrome could not be useful as a predictor of a correct diagnosis but each non motor 
domain will help to clarify and characterize the motor syndrome. In particular, the evaluation of  
cognitive impairment  will help to clarify the diagnosis, especially in typically clinical presentation, 
to define the atypical presentation  in clinical heterogeneous syndrome and to stratify the prognosis 
according to the severity of the disease.  
Furthermore, cognitive impairment has been related to different features of parkinsonian syndrome 
(older age at onset, worst motor phenotype, associated sleep and autonomic dysfunction, genetic 
background) probably related both to different pathways  and to advanced stage of 
neurodegeneration. 
In conclusion, the diagnosis of parkinsonian disorders lies in building a clinical profile in 
conjunction with other clinical characteristics such as mode of presentation, disease progression, 
response to medications, sleep and autonomic features. Taken together, these clinical features will 
aid the clinician in making an accurate antemortem diagnosis and hence a prediction of underlying 
pathology. 
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Figure 3. Evolution of cognitive impairment in progressive and not progressive patients 
  
 
Table 1. Diagnostic criteria of parkinsonian syndromes.  
! PD PSP C BD MSA L BD 
Inher itance !   Sporadic !
Age at onset ! 40 or later  >30 y Progressive 
Onset Progressive Progressive Progressive Rapidly Progressive  
Disease 
duration 3 years at least Postural instability  with falls  < 1 yr disease onset  Postural instability within 3 y of motor onset  
 Clinical course of 10 ys 
or more Early dysphagia & dysarthria  Dysphagia within 5 y of motor onset   
Motor signs Asymmetric onset 
Resting tremor  
Symmetric akinesia or rigidity  
proximal> distal asymmetric onset bradykinesia with rigidity, tremor, or postural instability  parkinsonism 
 Bradykinesia  akinetic rigid syndrome  
gait ataxia with cerebellar dysarthria, limb ataxia, or 
cerebellar oculomotor dysfunction 
bradykinesia with rigidity, tremor, or 
postural instability 
 Rigidity   Dysphagia  !
    Severe dysarthria and dysphonia !
    Pathologic laughter or crying !
  Either vertical supranuclear palsy or limb dystonia Orofacial dystonia  !
  both slowing of vertical saccades   Disproportionate antecollis !
  early dysphagia & dysarthria  Camptocormia  !
    Pisa syndrome  !
  abnormal neck posture retrocollis  Postural instability !
   reflex myoclonus  focal myoclonus Jerky, myoclonic postural/action tremor  !
    Contractures of hands or feet !
    Babinski sign with hyperreflexia !
Table 2. Secondary causes of parkinsonism  
? 
??  
Diagnosis E tiology 
Medication induced 
 
Neuroleptics   
Lithium 
Valproic acid  
Calcium channels blockers 
Structural 
 
Vascular (vascular parkinsonism)  
Subdural haematoma 
Trauma (dementia pugilistica)   
Normal pressure hydrocephalus 
Toxins 
 
Manganese   
Carbon monoxide 
MPTP  
Carbon disulfide 
Mercury   
Cyanide  
Methanol   
Organophosphates 
Solvents   
Pesticides 
(Post) infectious 
 
HIV   
Measles 
Encephalitis lethargica   
Epstein?Barr virus 
Japanese encephalitis   
West Nile virus 
Coxsackie B virus   
Neurosyphilis 
Metabolic 
 
Hypoparathyroidism   
GM1 gangliosidosis 
Hypothyroidism   
Addison's disease 
Uraemia   
Hypoxia 
Carbon monoxide 
 
? 
? 
 
Function Test Range Reference
Global Cognition MMSE 0-30; cut-off: > 22 Folstein et al, 1975
Brief  Mental Deterioration Battery Gallassi et al., 1986, 2002, 2008
Raven Progressive Matrices 0-38; cut- off 
Memory Rey’s 15 words: immediate recall 0–75; cut-off: >28.53 Carlesimo et al., 1996
Rey’s 15 words: delayed recall 0–15; cut-off: >4.69 Carlesimo et al., 1996
Paired-associated word learning test 0–22.5; cut-off: >8.73 De Renzi et al., 1977
Immediate visual memory 0–22; cut-off: >13.85 Carlesimo et al., 1996
verbal working memoryForward verbal span 0–9; cut-off: > 4,26 Monaco et al., 2012
Backward verbal span 0–8; cut-off: > 2,65 Monaco et al., 2012
Attention Barrage test result: cut-off: <2.5 Gallassi et al., 1986, 2002
Stroop test: time cut-off: ! 27.5 Caffarra et al., 2002
Stroop test: errors cut-off: ! 7.5 Caffarra et al., 2002
Trail Making Test A 0-infinite; cut-off: <93 Giovagnoli et al, 1996
Language                            fluency Verbal Fluency: phonemic  0–infinite; cut-off:>17.35 Carlesimo et al., 1996
Verbal Fluency: semantic 0–infinite; cut-off: >25 Novelli et al., 1986
comprehensionToken Test
Visuo-spatial function Rey-Osterrieth complex figure copy 0-36; cut-off:" 28,87 Caffarra et al., 2002
Rey-Osterrieth complex figure recall 0-36;cut-off: " 9,46 Caffarra et al., 2002
Judgement of line orientation 0-30; cut-off <18
 working memoryCorsi Block Test 0–9; cut-off: > 3,46 Monaco et al., 2012
Executive function Simple Verbal Analogies Test 0–20; cut-off: >13,92 Gallassi et al., 1986; 2002; 2014
Trail Making Test B 0-infinite; cut-off: <282 Giovagnoli et al, 1996
Trail Making Test B-A 0-infinite; cut-off: <186 Giovagnoli et al, 1996
Wisconsin sorting card  test 0-infinite; cut-off: >0
Table 3. Description of cognitive and behavioral evaluation
Digit symbol test 0-infinite; cut-off<34
Praxis Bucco-facial  and trunk praxis 0-20; cut-off:> 16 Spinnler et al.,  1987
Ideomotor praxis 0-20; cut-off: >16 Spinnler et al., 1987
Ideative praxis 0-20; cut-off: >16 Spinnler et al., 1987
Constructional PraxisCopy design: simple 0–12; cut-off: >7.18 Carlesimo et al., 1996
Cortical sensibilities Digital agnosia 0-24; cut-off: > 13,75 Spinnler et al., 1987
Behavioral assessment
Neuropsychiatric Inventory
Beck Depression Inventory
STAI trait and state 
Apathy scale 
Evaluation of impulsive control 
disorder through (nMIDI)
0-30; cut-off: >9
0-infinite; cut-off :>50
0-72; cut-off: >44
Table 3. Description of cognitive and behavioral evaluation
Table 4. Characteristics of drop-out patients.  
 
 
 
 
 
 
Legend: 1 male; 2 female. 
Patient 
number 
Sex 
 
Age at onset 
(years) 
Age at first evaluation 
(years) 
Disease duration at T0 
(months) 
UPDRS at T0 
23 2 40 42 24 8 
29 1 44 45 12 17 
30 1 68 69 12 24 
47 1 72 74 24 30 
52 1 50 48 18 10 
58 1 71 73 24 28 
Table 5. Demographic and clinical data  
 
 
G roup Sex 
 
Education 
(years) 
Age at onset 
(years) 
Disease  
duration at T0 
(months) 
UPDRS T0 UPDRS T1 L E D T0 L E D T1 
Whole Sample 35 M/20 F 10,62 ±4,46 58,56±10,50 19,03±9,8 18,48±8,67 20,74±3,21! 78±167 298±169 
Cognitively normal         
Whole (37) 22 M/15 F 12,20±4,14 57,37±11,20 18,32±10,32 17,41±7,88 17,54 ±9,80 44±125 269±174 
PD (28) 17 M/11 F 12,65±4,14 57,57±12,08 16,17±9,79 15,51±6,96 13,84±5,15 35±107 223±114 
PS (9) 5 M/4 F 13,20±4,21 56±9,31 25±10,17 23,11±8,59 29,12±12,63 72±158 373±249 
Progressively 
cognitively impaired  
       
Whole (18)  13 M/5 F 8,20±4,08 61±8,2 20,5±8,48 20,61±9,78 26,61±16,45 152±225 354±149 
PD (11) 8 M/3 F 10,24±4,13 61,90±7,71 17,72±9,12 16,34±8,72 18±10,87 119±205 345±154 
PS (7) 5 M/2 F 7,50±2,26 59,57±9,46 24,85±5,39 27,28±7,69 40,14±14,85 215±266 370±166 
PD-M C I 2 M 14±2 58±4,24 21,5±20,50 18±12,72 23,5 ± 21,92 300±424 510±127 
Table 6.  Neuropsychological evaluation at T0 
!
 
 
 
 
 
 
 
 
 
 
 
 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD
education 10,62 4,46 12,65 4,14 13,20 4,21 10,24 4,13 7,50 2,26 5 10,5 7,78 3,50 2,12
age  at T0 60,03 10,37 57,12 10,83 56,60 12,34 63,71 9,81 59,33 8,66 61 65,5 12,02 66,00 1,41
M M SE 27,17 2,05 28,06 1,27 27,56 0,90 26,73 2,07 27,79 1,35 28,27 26,305 2,84 21,65 3,18
F R B B D M 1,65 0,96 2,26 0,61 2,50 0,69 1,32 0,83 1,06 0,73 1,12 1,74 1,43 -0,43 0,08
ST VM 40,36 9,38 46,58 9,22 43,15 6,93 36,41 8,30 38,27 4,41 46,4 40 7,07 25,58 11,99
L T VM 7,71 2,62 9,10 2,57 8,89 2,79 6,47 2,43 6,75 2,29 9,2 9,2 1,56 6,45 0,92
I VM 18,79 2,44 19,80 1,35 20,43 1,05 18,42 2,53 17,91 2,29 13,4 19,1 3,96 19,00 11,31
B arr T 55,35 22,24 46,18 11,34 42,80 8,20 56,24 18,99 59,83 25,10 65 122,5 45,96 70,00 4,84
B arr P 11,19 1,91 11,71 1,40 11,20 1,64 11,24 1,67 10,50 1,87 12 12,5 0,71 6,50 1,41
B arr E 0,98 2,26 0,41 0,71 0,60 1,34 0,62 1,60 3,33 5,09 4 0 0,00 3,00 0,71
B arr R 0,68 2,54 -0,38 0,75 -0,13 1,32 0,38 1,78 3,53 5,43 4,18 2,105 1,38 3,09 4,24
SC D 10,66 1,83 11,19 0,82 11,31 0,66 10,84 1,49 11,25 1,01 7,9 6,175 4,07 6,50 4,95
SVA T 15,81 2,42 16,73 1,27 17,70 1,45 14,98 3,01 14,69 1,48 15,53 18,38 0,20 12,94 4,24
WF 30,71 10,17 37,24 9,94 35,70 10,45 26,57 8,94 29,47 6,65 27,3 25,65 4,60 16,58 4,18
FS 41,09 9,16 47,06 7,45 40,40 6,58 37,10 8,96 40,33 8,07 49 43 16,97 20,00 3,57
Stroop T 23,17 14,04 17,09 5,15 15,20 7,16 25,52 13,94 27,54 10,57 36,5 35,875 30,23 37,75 2,21
Stroop E 2,49 6,62 0,15 0,49 -0,20 0,27 3,65 8,72 1,48 2,69 -1 7,29 8,90 17,00 6,61
W CS T -2,00 10,61 -5,25 16,10 -0,33 1,96 0,60 3,01 4,05 0
RF copy 33,97 4,19 34,25 2,78 35,29 0,56 35,96 1,37 30,50 7,43 34,08
RF recal l 19,57 5,49 24,13 3,66 20,69 2,01 19,39 5,63 14,67 6,22 19,03
FS 6,65 1,15 6,75 1,94 5,92 1,42 6,46 0,75 7,25 0,50 6,5
BS 4,76 1,31 5,17 1,17 5,33 1,53 4,67 1,21 4,20 1,79 4
CS 4,86 0,96 5,17 1,34 5,50 0,66 4,79 0,68 4,20 1,02 5
T M T A 42,19 20,06 49,60 27,15 39,67 6,11 31,20 16,45 39,38 16,86 79
T M T B  68,28 42,53 68,60 49,94 62,33 14,19 48,40 44,56 88,75 55,79 102
T M T B-A 26,78 32,61 27,20 40,70 19,33 16,17 23,20 36,08 37,25 45,09 23
PA W 10,36 4,88 13,24 4,73 15,46 1,74 8,14 3,51 7,05 5,36 10,55
B L 25,45 3,41 26,40 2,30 28,00 1,73 26,50 2,07 21,40 4,16 27
M P 29,73 3,19 31,60 1,65 31,77 1,82 28,95 4,00 27,72 3,57 28,9
Token 32,84 2,26 32,73 3,09 31,63 4,07 33,17 2,11 32,85 1,98 33,8
F A B 15,76 2,26 16,82 1,85 15,95 1,06 15,62 3,50 14,98 1,65 14,9
C B D PSP
I M PA IR E D
WH O L E 
SA M PL E
N O T I M PA IR E D
PD PSPD PS M SA
Table 7. Neuropsychological evaluation at T1 
!
!
!
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD
age  at T1 60,87 11,87 56,09 13,77 58,20 12,40 65,19 9,65 60,17 8,30 62,00 66,50 13,44 66,50 2,12
M M SE 27,57 2,23 28,37 1,40 28,58 2,38 27,53 2,18 27,66 1,32 26,27 24,01 3,26 22,65 4,60
F R B B D M 1,70 0,97 2,25 0,73 2,22 0,46 1,38 0,84 1,36 0,90 1,21 2,39 -0,46 0,13
ST VM 42,57 9,71 46,07 6,24 40,65 5,46 40,18 11,01 43,79 6,54 49,25 43,40 9,05 19,68 3,64
L T VM 8,04 2,68 8,01 2,74 8,11 2,58 8,08 2,40 8,16 2,35 10,40 10,35 1,06 5,45 0,49
I VM 19,39 2,64 20,80 1,27 20,30 1,75 18,23 2,77 20,70 3,23 16,55 18,45 1,06 13,78 0,49
B arr T 56,85 27,38 45,22 15,80 33,80 6,46 59,57 24,66 61,33 2,02 110,00 91,00 0,21 105,00 2,93
B arr P 10,43 2,21 11,17 1,77 10,40 1,34 10,38 2,06 9,17 37,85 7,00 13,00 6,50 53,74
B arr E 0,69 1,48 0,35 0,71 0,20 0,45 0,76 1,61 0,33 1,33 5,00 0,00 3,00 4,95
B arr R 0,67 2,13 -0,22 1,06 -0,68 0,73 0,78 2,16 1,09 0,52 8,05 1,14 4,56 4,24
SC D 10,65 1,85 11,26 1,09 11,56 0,65 10,65 1,59 10,37 1,62 10,00 6,10 7,13 2,11
SVA T 16,27 2,94 17,93 1,76 18,05 1,38 15,34 2,98 14,66 2,45 16,50 15,00 13,00 4,28
WF 32,64 11,97 38,09 10,68 37,59 14,62 29,79 11,63 31,72 3,00 33,60 20,30 7,07 14,58 2,12
FS 41,25 9,31 45,65 8,51 43,60 7,33 38,29 7,57 42,00 11,62 44,00 29,50 2,69 30,00 3,78
Stroop T 25,63 14,07 17,66 5,20 15,50 6,04 31,90 14,70 29,25 10,88 26,50 14,50 13,44 45,75 1,41
Stroop E 2,20 6,08 0,24 1,04 0,00 0,00 2,79 6,49 4,00 12,15 0,00 0,00 15,25 39,24
W CS T -3,20 9,06 -4,96 11,30 -0,66 2,14 -0,84 1,96 2,21 10,81
RF copy 31,82 6,17 33,39 3,19 30,76 7,69 30,15 3,13
RF recal l 17,67 7,00 21,54 5,63 15,10 7,02 16,18 2,40
FS 5,96 1,04 5,81 1,13 5,92 1,11 5,08 1,11
BS 4,45 1,30 4,45 0,69 3,50 0,71 4,43 2,07 7,25 2,09
CS 4,79 0,60 4,94 0,30 4,77 0,78 5,00 1,00
T M T A 37,96 25,75 44,13 26,35 39,00 29,71 22,50 12,73
T M T B  82,25 58,23 66,88 34,44 102,00 72,28 128,17 46,97
T M T B-A 53,13 44,04 57,08 45,03 29,00 42,07 60,81 30,12 53,75 51,97
PA W 7,36 3,37 8,93 3,08 5,57 1,62 5,50 2,01
B L 22,45 5,37 22,75 3,95 24,00 4,86 23,50 4,32
M P 26,54 3,83 28,54 3,13 26,20 3,61 28,60 10,21
Token 30,10 3,35 31,25 2,19 29,33 3,95 22,00 1,12
F A B 14,68 3,51 15,99 1,84 13,54 4,60 15,00 3,88
N O T I M PA IR E D I M PA IR E D
WH O L E PD PS PD PS M SA C B D PSP
Table 8. Impaired test and function of brief evaluation in the whole sample 
 
  Progressive patients (18 patients) Not progressive (37  patients) 
B rief battery T0 T1 T0 % T1 % T0 T1 T0 % T1 % 
MMSE 3 3 9,17 9,17 0 0 0,00 0,00 
FR BBDM 3 5 9,17 15,28 0 0 0,00 0,00 
LTVM 1 4 3,06 12,22 2 0 2,97 0,00 
IVM 1 1 3,06 3,06 2 2 2,97 2,97 
CD 2 4 6,11 12,22 1 2 1,49 2,97 
BARR 3 6 9,17 18,33 4 3 5,95 4,46 
STVM 4 4 12,22 12,22 0 1 0,00 1,49 
FS 5 5 15,28 15,28 4 0 5,95 0,00 
SVAT 6 11 18,33 33,61 3 1 4,46 1,49 
WF 6 6 18,33 18,33 1 0 1,49 0,00 
STROOP 10 14 30,56 42,78 6 6 8,92 8,92 
Global impairment  3 3 9,17 9,17 0 0 0,00 0,00 
Verbal Memory 4 7 12,22 21,39 3 3 4,46 4,46 
Attention  10 15 30,56 45,83 9 7 13,38 10,41 
Praxis  2 4 6,11 12,22 0 1 0,00 1,49 
Fluency 6 7 18,33 21,39 4 1 5,95 1,49 
Executive function  7 12 21,39 36,67 4 1 5,95 1,49 
Table 9. Impaired test and function of comprehensive evaluation in the whole sample 
!
!
!
Progressive patients (7 patients) Not progressive (13 patients) 
Comprehensive battery T0 T1 T0 % T1 % T0 T1 T0 % T1 % 
MMSE 0 0 0,00 0,00 0 0 0,00 0,00 
FR BBDM 0 0 0,00 0,00 0 0 0,00 0,00 
STVM 0 0 0,00 0,00 2 0 3,08 0,00 
LTVM 0 0 0,00 0,00 1 2 1,54 3,08 
IVM 0 1 0,00 2,86 0 0 0,00 0,00 
BARR 0 0 0,00 0,00 1 0 1,54 0,00 
CD 0 0 0,00 0,00 0 1 0,00 1,54 
SVAT 1 1 2,86 2,86 1 1 1,54 1,54 
WF 0 0 0,00 0,00 2 1 3,08 1,54 
FS 0 0 0,00 0,00 0 0 0,00 0,00 
STROOP 1 3 2,86 8,57 3 2 4,62 3,08 
WCST 3 5 8,57 14,29 8 9 12,31 13,85 
RFC 0 0 0,00 0,00 0 0 0,00 0,00 
FS 0 0 0,00 0,00 1 0 1,54 0,00 
BS 0 0 0,00 0,00 0 0 0,00 0,00 
CS 0 0 0,00 0,00 0 0 0,00 0,00 
TMT  0 0 0,00 0,00 0 0 0,00 0,00 
PAW 0 2 0,00 5,71 4 0 6,15 0,00 
BL 0 1 0,00 2,86 0 0 0,00 0,00 
MP 0 0 0,00 0,00 0 0 0,00 0,00 
Token 0 0 0,00 0,00 0 0 0,00 0,00 
FAB  0 1 0,00 2,86 1 0 1,54 0,00 
Praxis 0 0 0,00 0,00 0 0 0,00 0,00 
Cortical sensibilities 0 0 0,00 0,00 1 1 1,54 1,54 
Global impairment  0 0 0,00 0,00 0 0 0,00 0,00 
Verbal Memory  0 2 0,00 5,71 4 2 6,15 3,08 
Attention  1 3 2,86 8,57 4 2 6,15 3,08 
Praxis  0 0 0,00 0,00 0 1 0,00 1,54 
Fluency 0 0 0,00 0,00 2 1 3,08 1,54 
Comprehension  0 0 0,00 0,00 0 0 0,00 0,00 
Executive function  3 6 8,57 17,14 9 10 13,85 15,38 
Visuo spatial memory 0 1 0,00 2,86 0 0 0,00 0,00 
Working memory  0 0 0,00 0,00 0 0 0,00 0,00 
Praxis 0 0 0,00 0,00 0 0 0,00 0,00 
Cortical sensibilities 0 0 0,00 0,00 1 1 1,54 1,54 
Table 10. Characteristics of patients with RBD.  
 
Legend: CI: cognitive impairment, Y: yes, N: no; MMSE: Mini Mental State Evaluation 1 male; 2 female. 
Diagnosis C I 
(Y/N) 
 (M MSE) Sex 
 
Age at onset 
(years) 
Disease duration  
at T0 
(months) 
Age 
at 
RBD 
onset 
UPDRS  
at T0 
UPDRS  
at T1 
 
8 PS N 27,9 1 63 55 61 22 26  
12 MSA N 26,27 2 58 52 20 31 40  
21 PD N 26,7 2 76 28 - 7 8  
35 PD N 25,7 1 68 34 69 14 15  
38 PD  N 28,27 1 62 26 30 14 15  
10 PD Y 20,97 1 55 52 55 27 39  
51 PS Y 25,33 1 59 40 58 22 29  
57 PS Y 27 1 64 34 65 22 33  
60 PS Y 28,46 1 43 40 39 21 47  
Table 11. Diagnostic criteria for Parkinson Disease ?Mild Cognitive Impairment (PD-MCI).   
 
Criteria for the Diagnosis of PD-MCI  
comprehensive assessment 
(Neuropsychological testing that 
includes two tests within each of the 
five cognitive domains -!attention and 
working memory, executive, language, 
memory, and visuospatial) 
 
Impairment on at least two neuropsychological tests,  
represented by either two impaired tests in one cognitive domain  
or one impaired test in two different cognitive domains 
Impairment on neuropsychological tests may be demonstrated by: 
-Performance approximately 1 to 2 SDs below appropriate norms 
or significant decline demonstrated on serial cognitive testing  
or significant decline from estimated premorbid levels 
Subtype classification for PD-MCI PD-MCI single-domain 
?abnormalities on two tests within a single cognitive domain 
(specify the domain), with other domains unimpaired  
PD-MCI multiple-domain 
?abnormalities on at least one test in two or more cognitive 
domains (specify the domains) 
 
Table 12. Comparison of cognitive deficit in parkinsonian syndromes (modified from  36, 39, 40). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Function PD PDD PSP D C B MSA 
Memory 
 
Mild,inconstant 
recall deficit, 
 
Mild-moderate 
information storage 
impairment 
Impaired recall and 
access to stored 
information 
Mild, inconstant 
episodic memory 
impairment 
 
Inconsistent 
results 
Learning 
Categorization deficit, long 
span, implicit learning 
 
Categorization deficit, 
more implicit 
than  explicit learning 
deficit 
 
Implicit procedural deficit, 
explicit 
learning deficits 
compensated 
by semantic cues 
Explicit learning 
deficits 
compensated by 
using semantic cues 
Inconsistent 
results 
Executive 
functions 
Mild planning; 
Problem solving; 
concept-formation; 
abstract reasoning 
Moderate planning; 
problem-solving; 
concept-formation; 
abstract reasoning 
Severe and early 
planning; problem-solving; 
concept-formation; 
abstract 
reasoning 
 
Mild to moderate 
planning; problem 
solving; 
concept- formation; 
abstract 
reasoning 
Mild planning; 
Problem solving; 
concept-
formation; 
abstract 
reasoning 
Language Decreased fluency Decreased fluency  
Decreased letter 
fluency; transcortical 
motor or 
dynamic aphasia 
Decreased semantic 
fluency, yes/no 
reversal; 
transcortical motor/ 
Broca/anomic 
aphasia, PPA 
Decreased 
fluency 
Praxis 
No ideomotor 
apraxia, 
constructional 
apraxia may be 
present 
Ideomotor apraxia 
may be present, 
but no asymmetric 
apraxia. 
Constructional 
apraxia 
Mild ideomotor 
apraxia, no 
ideatory apraxia 
Ideomotor > ideatory 
Apraxia,  constructional 
apraxia 
Inconsistent 
results 
V isuo-spatial 
functions 
Horizontal plane 
attention, spatial 
perception, 
visuomotor 
coordination 
spatial imagery 
Mild or absent 
Visual grasping; 
vertical plane 
inattention; 
spatial perception 
Horizontal neglect; 
Balint-Holmes 
syndrome 
Inconsistent 
results 
 Table 13.  Cognitive testing in the diagnosis of parkinsonian disorders (modified from 39, 40) 
  
 PSP D C B MSA 
PD Phonemic fluency  
Semantic fluency 
WCST 
TMT A time and errors 
FAB * 
Orofacial apraxia TMT ?B E 
STROOP E 
PSP  Orofacial apraxia  
MSA Phonemic fluency  
Semantic fluency 
WCST 
Orofacial apraxia  
 
 
 
 
 
 
 
 Table 14. Behavioural characteristics of parkinsonian syndromes (modified from 39). 
 
 
 
!
!
!
!
!
!
Legend: -:absent;  +: rare;  ++:present  +++:usually early and severe symptom.  
!
!
Function PD PDD PSP D C B MSA 
Apathy + + +++ - + 
Depression ++ ++ + ++ + 
Hallucination; delusions; delusional 
misidentification;fluctuation ++  +++ - - - 
I r r itability + + + - + 
Dishinibition ++ ++ ++ - - 
Anxiety-agitation ++ ++ - - + 
Utilization, imitation, 
prehension behaviors ++ ++ +++ - + 
 F igure 1. Progression of cognitive impairment 
!
 F igure 2. Percentage of patients failing each neuropsychological test in progressive (a) and not 
progressive (b) patients. 
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 F igure 3. Evolution of cognitive impairment in progressive and not progressive patients 
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